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Abstract: Disturbances of hippocampal plasticity, including impaired dendritic branching 
and reductions of neurogenesis, are provoked by stressful insults and may occur in depression. 
Although corticoids likely contribute to stressor-induced reductions of neurogenesis, other signal-
ing messengers, including pro-inﬂ  ammatory cytokines might also be involved. Accordingly, the 
present investigation assessed whether three proinﬂ  ammatory cytokines, namely interleukin-1β 
(IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) (associated with depression) inﬂ  uenced 
cellular proliferation within the hippocampus. In this regard, systemic administration of TNF-α 
reduced 5-bromo-2-deoxyuridine (BrdU) labeling within the hippocampus, whereas IL-1β and 
IL-6 had no such effect. However, repeated but not a single intra-hippocampal infusion of IL-6 
and IL-1β actually increased cellular proliferation and IL-6 infusion also enhanced microglial 
staining within the hippocampus. Yet, no changes in doublecortin expression were apparent, 
suggesting that the cytokine did not inﬂ  uence the birth of cells destined to become neurons. 
Essentially, the route of administration and chronicity of cytokine administration had a marked 
inﬂ  uence upon the nature of hippocampal alterations provoked, suggesting that cytokines may 
differentially regulate hippocampal plasticity in neuropsychiatric conditions.
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Introduction
Recent efforts assessing the mechanisms of depression have focused on the possibility 
that immune factors, particularly cytokines, may contribute to this disorder. Besides 
being responsible for communication between immune cells, these messengers also 
act as immunotransmitters, alerting the central nervous system of immunological 
insults.1–4 In this regard, the proinﬂ  ammatory cytokines, interleukin-1β (IL-1β) 
and tumor necrosis factor-α (TNF-α), and IL-6 to a lesser extent, stimulated hypo-
thalamic–pituitary–adrenal (HPA) activity and augmented turnover of serotonin 
(5-HT) and norepineprine (NE) in several stressor-sensitive hypothalamic and extra-
hypothalamic brain regions.5–7 Moreover, an IL-1 receptor antagonist attenuated the 
neurochemical effects of a restraint stressor,8 suggesting that the stressor was acting 
through cytokine dependent mechanisms. Beyond these effects, IL-1β and TNF-α 
induced behavioural alterations (eg, anhedonia) that were reminiscent of the effects 
of stressors as well as those that are characteristic of depressive disorder.2,9–11 For 
instance, social exploration and responding for a palatable solution were signiﬁ  cantly 
decreased in rodents that received peripheral or central IL-1β administration.12–14
In addition to their neurochemical effects, cytokines, like stressors, may also inﬂ  u-
ence processes important for neuroplasticity, and hence may inﬂ  uence cognitive and 
affective functioning. In fact, IL-1β and TNF-α were reported to alter hippocampal 
long-term potentiation and together with IL-6, also inﬂ  uenced dendritic branching Neuropsychiatric Disease and Treatment 2009:5 6
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of hippocampal neurons.15 Similarly, depressed individuals 
were reported to display elevated levels of these cytokines 
along with cognitive deﬁ  cits, which in some cases may be 
coupled with reductions of the growth factor, brain-derived 
neurotrophic factor (BDNF), as well as decreased hippo-
campal volume.16–20
Impairment in the generation of new hippocampal cells 
has been implicated in the altered hippocampal plasticity 
observed in depressed subjects and animals exposed to 
various stressors.21–24 The impact of stressful challenges 
upon neurogenesis or gliogenesis appears to vary with 
the type of stressor and chronicity of exposure. Indeed, 
chronic but not acute restraint reduced the proliferation 
of newly born dentate gyrus cells;25 however, an acute 
psychosocial stressor did reduce the survival of recently 
generated hippocampal cells.26 Importantly, disturbances 
of neurogenesis may have functional implications for 
depression, as indicated by the ﬁ  nding that the behavioral 
effects of the antidepressants, ﬂ  uoxetine and imiprimine, 
were ameliorated by selective impairment of hippocampal 
neurogenesis.27
Although it is clear that glucocorticoid elevations associ-
ated with depression and stressor exposure can impair the 
birth of hippocampal cells,20,28,29 pro-inﬂ  ammatory cytokines 
may also contribute in this regard. Indeed, using a dosing 
schedule similar to that used clinically to treat cancer and 
viral infection and which also elicits symptoms of depression, 
administration of interferon-α (IFN-α) reduced hippocampal 
neurogenesis in rodents, and this effect was dependent upon 
endogenous IL-1β levels.30 In agreement with this ﬁ  nd-
ing, the reduction of hippocampal neurogenesis normally 
associated with chronic stressor exposure was prevented 
in IL-1 type 1 receptor knockout mice.31 Likewise, altera-
tions of hippocampal neurogenesis were reported in adult 
transgenic mice over-expressing IL-6,31 and administration 
of the bacterial endotoxin lipopolysaccharide (LPS) sup-
pressed neurogenesis while concomitantly elevating IL-1β 
and TNF-α.32 The effects of LPS on neurogenesis were 
reversed by the tetracycline derivative, minocycline, or the 
nonsteroidal anti-inﬂ  ammatory compound, indomethacin, 
both of which are potent inhibitors of inﬂ  ammatory cytokines 
and microglia.32,33
Cytokines may inﬂ  uence neuroplasticity through actions 
upon peripheral sites, such as vagal afferents, receptors at 
the blood brain barrier or immune cells, or by directly act-
ing within the central nervous system (CNS).34–36 Hence, 
the current study assessed the impact of systemic and 
intra-hippocampal infusion of the cytokines, IL-1β, IL-6 
and TNF-α upon the generation of new dentate gyrus cells. 
Since the chronicity of stressor exposure greatly inﬂ  uences 
the nature of neuroplastic effects imparted by such chal-
lenges,25 it was also of interest to evaluate whether the 
effects the cytokines were augmented or diminished with 
repeated infusion. Presently, we report that systemic TNF-α 
dramatically reduced the generation of new dentate gyrus 
cells that incorporated the cellular proliferation marker, 
5-bromo-2-deoxyuridine (BrdU), whereas infusion of the 
cytokine directly into the hippocampus had no such effect. 
In contrast, repeated but not a single intra-hippocampal infu-
sion of IL-6 induced a profound elevation of hippocampal 
cells expressing BrdU, together with enhanced microglial 
reactivity. Thus, a single TNF-α exposure may negatively 
inﬂ  uence the production of hippocampal cells by affecting 
peripheral processes, whereas repeatedly elevated IL-6 may 
act within the hippocampus to promote cellular prolifera-
tion. However, since no changes in immunoreactivity for 
the immature neuronal marker, doublecortin, were evident 
following the treatments, it appears that the cytokines did 
not inﬂ  uence the rate of neurogenesis. These data suggest 
that cytokine alterations provoked by stressful or inﬂ  am-
matory challenges may inﬂ  uence hippocampal plasticity 
and that such effects may vary according to the speciﬁ  c 
cytokine(s) involved, as well as the physiological region 
and chronicity of exposure.
Methods
Animals
Each of the two experiments involved naïve, male CD-1 mice 
obtained from Charles River Canada (Laprairie, Quebec) 
at 8–10 weeks of age. Mice were permitted 2–3 weeks 
to acclimatize to the laboratory before the start of each 
experiment. Mice were housed in groups of four in standard 
(27 × 21 × 14 cm) polypropylene cages and transferred to 
individual housing 1 week before the initiation of a study. 
Animals were kept on a 12-h light–dark cycle (lights on: 
0800–2000 hours) in a temperature-controlled vivarium 
(22–25 °C), and were provided free access to mouse chow 
and water. All experimental procedures complied with the 
current guidelines stipulated by the Canadian Council on 
Animal Care and were approved by the Carleton University 
Animal Care Committee.
Surgery and cytokine treatments
Experiment 1
It was of interest to determine the effect of systemic proin-
flammatory cytokine administration upon hippocampal Neuropsychiatric Disease and Treatment 2009:5 7
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neuroplasticity. To this end, animals (n = 8/group) received 
intraperitoneal (i.p.) administration of either IL-1β (0.1 µg), 
IL-6 (1.0 µg), TNF-α (1.0 µg) or vehicle. In order to later 
examine and quantify any changes in cellular proliferation, 
animals were injected with 5-bromo-2-deoxyuridine (BrdU), 
an exogenous cell proliferation agent widely used to label 
mitotically active cells. Speciﬁ  cally, mice received one 
i.p. injection of BrdU (200 mg/kg; Sigma-Aldrich, Toronto, 
ON) dissolved in 0.9% saline immediately prior to the cyto-
kine or vehicle injection.
Experiment 2
This experiment assessed whether cytokines inﬂ  uence cel-
lular proliferation by directly acting within the hippocam-
pus, as opposed to activating peripheral immune substrates, 
which in turn, inﬂ  uence CNS processes. Thus, animals 
were stereotaxically implanted with a 33 gauge guide can-
nula just above the hippocampus (placement coordinates: 
A/P = −1.82 mm, D/V = −1.25 mm, M/L = ± 1.00 mm). 
Following a four day recovery period, mice (n = 6/group) 
were subjected to either a single infusion or ﬁ  ve days 
of once-daily infusions of saline, IL-1β (0.01 µg), IL-6 
(0.05 µg) or TNF-α (0.05 µg). Cytokines were dissolved in 
vehicle and in all cases 2 µL of solution was slowly infused 
over a period of ﬁ  ve minutes using a Pico Plus syringe 
pump (Harvard Apparatus Inc., Holliston, MA). In order to 
label dividing cells, animals received one i.p. injection of 
BrdU (200 mg/kg) immediately prior to the ﬁ  nal cytokine 
or saline injection.
Tissue preparation
At 24 hours after all cytokine or vehicle injections, animals 
were overdosed with pentobarbital and transcardially 
perfused with 0.9% saline, followed by 4% paraformalde-
hyde (PFA). Brains were collected, postﬁ  xed for 24 hours 
in PFA and then cryoprotected, for at least 3 days, in a 
20% sucrose solution with 0.02% azide. Using a cryostat, 
20-µm thick coronal hippocampal sections were collected 
and mounted on gelatine-coated slides. Ten slides were 
collected (6 sections/slide) from each brain and stored 
at −80 °C pending analysis. Hippocampal levels collected 
were operationally deﬁ  ned as early/rostral (bregma −1.22 
to −1.82), middle (bregma −1.82 to −2.46) and late/caudal 
(bregma −2.46 to −2.92). Thus, data analyses assessed 
whether cytokine treatments preferentially affected pro-
liferation at speciﬁ  c anatomical levels of the hippocampal 
dentate gyrus. In all cases, cannula placement was veriﬁ  ed 
using cresyl violet staining.
Immunohistochemistry and quantiﬁ  cation 
procedures
Brain sections were processed for BrdU labeling by 
incubation in 1N HCl (2 hours at 50 °C) to denature DNA, 
followed by neutralization with 0.1M borate buffer (pH 8.5) 
for ten minutes. After rinsing with PBS (0.01 M), the sec-
tions were incubated with mouse monoclonal anti-BrdU 
(1:200 Sigma-Aldrich, Toronto, ON) for 48 hours at 4 °C. 
Thereafter, CY3 conjugated donkey anti-mouse (1:200; 
Jackson ImmunoResearch Laboratories Inc., PA) antiserum 
was used as the secondary antibody. Separate section were 
also processed in order to quantify whether changes in BrdU 
labeling reﬂ  ect variations of neurogenesis, as indicated 
by a transiently expressed marker of immature neurons, 
doublecortin (DCX). Thus, sections were incubated with 
anti-DCX (1:600; guinea pig polyclonal, Abcam, FL) for 
24 hours at 4 °C followed by anti-rabbit CY3 (1:200; Goat 
polyclonal to Guinea Pig, Abcam, FL) for one hour at room 
temperature.
Markers for astrocytes and microglia were also used in 
order to determine whether the cytokines inﬂ  uenced glial 
activity, such that sections were ﬁ  rst incubated with anti-
GFAP (1:500, mouse polyclonal, Chemicon International) 
or anti-CD11b (1:1000; rat monoclonal, Raleigh, NC) for 
24 hours at 4 °C. Subsequently, the sections were incubated 
with CY3 conjugated donkey anti-mouse or ant-rat (1:200, 
Jackson Immunoresearch) antibodies for 2 hours at room 
temperature.
All quantitative analyses were performed under condi-
tions in which the rater was blind to the treatments received. 
For Experiment 1, the total number of bilaterally labeled 
BrdU-positive cells was counted within the rostral, middle 
and caudal portions of the dentate gyrus. Using 40X mag-
niﬁ  cation, the 20 µm tissue sections were counted and the 
average number of immuno-positive cells per section cal-
culated for each hippocampal level. For Experiment 2, the 
number of BrdU-positive cells of the ipsilaterally infused 
hemisphere was assessed.
Statistics
Data from Experiment 1 were analyzed at each hippocampal 
level using one-way ANOVAs, with IL-1β, IL-6, TNF-α, and 
control as factor levels for the treatment condition. Data for 
Experiment 2 were analyzed at each hippocampal level using 
two-way ANOVAs, with chronicity (acute and sub-chronic) 
and treatment (IL-1β, IL-6, TNF-α, and control) as factors. 
Post hoc Tukey tests were performed to determine speciﬁ  c 
between-group differences (α = 0.05).Neuropsychiatric Disease and Treatment 2009:5 8
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Results
Experiment 1:   Acute systemic cytokine 
exposure alters hippocampal cell 
proliferation (BrdU) and neurogenesis 
(DCX)
Although no signiﬁ  cant effects were observed at the middle 
and caudal hippocampal levels, an ANOVA did reveal that the 
cytokine treatments provoked signiﬁ  cant differences in BrdU 
counts at the rostral level of the hippocampus F(3, 23) = 3.02, 
p  0.05. Post hoc Tukey comparisons indicated that mice of 
the TNF-α group differed signiﬁ  cantly from saline-injected 
animals (p  .05). Indeed, as shown in Figure 1, mice that 
received i.p. administration of TNF-α had an approximately 
sevenfold reduction of BrdU labelling in the rostral portion 
of the dentate gyrus relative to those that received saline 
(Figure 1). Although IL-6 treatment seemed to reduce the 
number of proliferating cells, the observed results were 
relatively variable, precluding the detection of statistically 
signiﬁ  cant differences. With respect to the morphological 
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Figure 1 BrdU immunopositive cells are depicted in the photomicrographs of the rostral portion of hippocampal dentate gyrus of animals subjected to i.p. injection of 
A) saline, B) IL-1β (0.1 µg), C) TNF-α (1.0 µg) or (d) IL-6 (1.0 µg). There was a clear reduction of BrdU-labelled cells in mice that received TNF-α (panel C), relative to saline 
injected controls (panel A). The bottom bar graph displays the mean (± SEM) number of BrdU-positive cells per section and conﬁ  rms the suppression of BrdU labeling following 
systemic administration of TNF-α.
Notes: *p  0.05 vs. saline-treated animals, 10× magniﬁ  cation.Neuropsychiatric Disease and Treatment 2009:5 9
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aspects of the proliferating cells, BrdU-positive cells were 
generally small, oval-shaped and had a stippled pattern. They 
were mainly in the subgranular zone (SGZ) of the dentate 
gyrus and the hilus, often in clusters of two or three. These 
morphological characteristics and pattern of distribution 
closely resemble that ordinarily reported.37 Although no 
signiﬁ  cant treatment effects were observed in the middle and 
caudal levels of the hippocampus, there was a trend towards 
a cytokine-induced reduction of BrdU labelling, such that in 
the middle hippocampal region, IL-1β and TNF-α provoked 
a modest decrease in BrdU staining (35%–40% decrease) 
relative to saline treated mice (data not shown).
In contrast to the effects of TNF-α upon hippocampal 
BrdU incorporation, the cytokine treatments did not sig-
niﬁ  cantly inﬂ  uence expression of the immature neuronal 
marker, DCX, within the rostral, middle or caudal regions 
of the dentate gyrus Fs (3, 23) 1. For example, as shown in 
Figure 2, DCX immunoreactivity within the rostral dentate 
gyrus did not differ between mice that received either 
systemic TNF-α or vehicle.
Experiment 2:   A single and repeated 
central cytokine infusion differentially 
inﬂ  uence hippocampal cell proliferation 
(BrdU, CD11b)
Signiﬁ  cant variations of BrdU labelling were evident at 
each of the three hippocampal levels assessed. Indeed, at the 
most rostral level of the dentate gyrus BrdU labelling varied 
as a function of the interaction between intra-hippocampal 
cytokine infusion and chronicity of administration, 
F(3, 38) = 3.49, p  0.05. The follow up Tukey tests 
revealed that the repeated, but not single, intra-hippocampal 
IL-6 infusion signiﬁ  cantly increased the hippocampal BrdU 
labelling, relative to saline infused mice (p  0.05; Figure 3). 
Although the interaction failed to reach signiﬁ  cance at the 
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Figure 2 The photomicrographs (4× magniﬁ  cation) show doublecortin (DCX) positive immature neurons within the dentate gyrus of the rostral portion of dorsal hippocampus. 
There was no signiﬁ  cant difference in DCX expression between mice that received i.p. saline A) or those treated with i.p. TNF-α B) The inset (upper right corner of panel 
A) reveals a higher magniﬁ  cation (20×) image of the DCX positive soma and projections from a saline-treated animal.Neuropsychiatric Disease and Treatment 2009:5 10
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middle hippocampal level, the ANOVAs for the individual 
cytokine infusion and chronicity main effects were signiﬁ  -
cant, Fs (3,38) = 4.31, (1, 38) = 3.77, respectively, p  0.05. 
The post hoc analyses revealed that IL-1β and IL-6 infusion 
increased the number of BrdU positive cells relative to the 
respective saline treated animals and that repeated cytokine 
administration enhanced levels of the proliferation marker 
above that observed following a single acute treatment 
(p  0.05). Finally, ANOVA of the caudal portion of the 
dentate gyrus revealed that BrdU immunoreactivity varied as 
a function of the cytokine infusion and chronicity of admin-
istration F(3, 38) = 3.23, p  0.05. As shown in Figure 3, 
follow up analyses of the signiﬁ  cant interaction indicated 
that repeated infusion of IL-6 increased the number of BrdU 
positive cells at this level of the hippocampus, relative to the 
remaining groups (p  0.05). Of particular interest was the 
fact that repeated IL-6 infusion had the greatest impact on 
cell proliferation and this was evident at all three levels of 
the dentate gyrus. Importantly, BrdU levels were identical 
in animals that received either the single or repeated intra-
hippocampal saline infusion, suggesting that repeated vehicle 
infusion alone did not affect cellular proliferation. Surpris-
ingly, intra-hippocampal infusion of TNF-α failed to inﬂ  uence 
BrdU labelling, suggesting that the BrdU reduction observed 
in mice that received i.p. TNF-α in Experiment 1 may stem 
from actions of the cytokine at peripheral sites. The lack of 
an effect of TNF-α on BrdU incorporation may be related to 
the timing of sacriﬁ  ce or dose of the cytokine administered. 
Indeed, one report did indicate that central TNF-α infusion 
increased BrdU labelling; however, this study used a sub-
stantially higher dose of the cytokine (355 ng vs 50 ng used 
in the present study) and involved an intra-ventricular rather 
than intra-hippocampal route of delivery.59
As in the previous experiment, the BrdU-positive cells 
were located mainly in small clusters in the subgranu-
lar and the hilus regions of the dentate gyrus (Figure 3). 
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Figure 3 The photomicrographs depict BrdU-positive cells within the dentate gyrus following a single or repeated intra-hippocampal cytokine or saline infusion. Elevated 
BrdU staining within the dentate gyrus was observed in animals subjected to repeated intra-hippocampal infusion of either IL-1β (panel B) or IL-6 (panel C), relative to animals 
that received vehicle (panel A). The BrdU increase was particularly robust for the repeated IL-6 treatment. Quantiﬁ  cation of mean (± SEM ) number of BrdU-positive cells per 
section conﬁ  rmed that repeated (grey bars) but not a single (white bars) intra-hippocampal infusion of IL-1β and IL-6 signiﬁ  cantly increased BrdU staining, relative to animals 
that received infusion of saline.
Notes: *p  0.05 vs saline-treated animals, 10× magniﬁ  cation.Neuropsychiatric Disease and Treatment 2009:5 11
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However, some BrdU labelling was also observed just 
above the dentate gyrus and around the CA1 region of the 
hippocampus, possibly reﬂ  ecting migration of newly born 
neurons or alternatively, these cells may be of glial origin. 
Indeed, paralleling the BrdU variations, repeated but not a 
single IL-6 infusion provoked intense immunoreactivity for 
the microglial marker, CD11b, within the CA1 hippocampal 
region, directly above the granule cell layer of the dentate 
gyrus (Figure 4). In fact, a wave of CD11b labelling was 
apparent from the cannula tract into the corpus callosum and 
the hippocampus, suggesting that repeated IL-6 exposure 
activated microglial proliferation. In contrast, no signiﬁ  cant 
variations of staining the astrocyte marker, GFAP, or the 
immature neuronal marker, DCX, were evident among the 
treatment groups (data not shown). Thus, IL-6 appeared to 
be selectively affected microglia and not immature neurons 
or astrocytes.
Discussion
The present ﬁ  ndings are consistent with the proposition that 
variations of cytokines may impair hippocampal plasticity. 
In fact, we and others have previously posited that altera-
tions of hippocampal volume or neuroplasticity often asso-
ciated with depression may stem from stressor or cytokine 
induced disturbances of cellular proliferation, as well as 
other morphological abnormalities, such as reduced dendritic 
branching.2,21,23,24 Moreover, impairment of hippocampal 
cellular proliferation may have functional implications for 
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Figure 4 Photomicrographs of labeling for the microglial marker, CD11b, in animals subjected to a single or repeated intra-hippocampal infusions of saline or IL-6. The CD11b 
immunoreactivity was evident in the granule cell layer (GCL) of the dentate gyrus, as well as within the CA1 hippocampal region. Single (A) and repeated (B) infusion of saline 
provoked minimal CD11b staining in the GCL and CA1. Although the single IL-6 infusion (C) induced modest CD11b immunoreactivity, repeated infusion of the cytokine (D) 
produced the most marked increase of expression of the microglial marker within the GCL and CA1 areas of the hippocampus. 4× magniﬁ  cation.Neuropsychiatric Disease and Treatment 2009:5 12
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depression, especially as the efﬁ  cacy of antidepressants was 
reduced in the face of impaired hippocampal neurogenesis.27 
Yet, surprisingly little is known of the potential mechanisms 
through which stressors or other factors aligned with depres-
sion may impact upon hippocampal cellular proliferation.
In addition to their role in depressive-like pathology,2,9,11 
pro-inﬂ  ammatory cytokines might inﬂ  uence neurogenesis. 
Indeed, when administered chronically (in a schedule mim-
icking an immunotherapeutic protocol), IFN-α elicited a 
marked reduction of hippocampal neurogenesis.30 Interest-
ingly, the impact of IFN-α upon neurogenesis was ame-
liorated by central treatment with the cytokine antagonist, 
IL-1Ra, suggesting that endogenous IL-1β was an important 
factor inhibiting neurogenesis.30 Furthermore, IL-1 receptor 
knockout prevented the reduction of neurogenesis associated 
with a chronic stress regimen51 and attenuation of the inﬂ  am-
matory response using indomethacin likewise normalized 
the reduction of neurogenesis associated with endotoxin 
treatment or irradiation.32 Thus, there is reason to believe 
that inﬂ  ammatory cytokines may be involved in regulating 
neuroplastic mechanisms aligned with neurogenesis.
Systemic cytokine administration 
and hippocampal cellular proliferation
Presently, we report a marked reduction of cell prolifera-
tion, as indicated by BrdU incorporation, within the rostral 
portion of the hippocampal dentate gyrus (DG) following 
systemic administration of TNF-α. In contrast, the cytokine 
did not affect hippocampal DCX expression, suggesting 
that the variations of BrdU labelling reﬂ  ecting changes in 
the proliferation of non-neuronal cells, these could likely be 
glia given their marked sensitivity to cytokine signalling. 
Interestingly, intra-hippocampal TNF-α infusion did not 
signiﬁ  cantly affect hippocampal cellular proliferation. Thus, 
the peripheral rather than central actions of TNF-α may be 
most pertinent in affecting the birth of new DG cells. This is 
consistent with our previous ﬁ  ndings that systemic TNF-α 
elicited a marked elevation of corticosterone and sensitized 
mice to the impact of subsequent exposure to the cytokine, 
whereas central infusion of the cytokine had only modest 
actions upon hormone levels and did not provoke such a 
sensitization.5
We have previously found that IL-1β (even at 4 fold 
lower doses) generally produces more profound behavioral, 
neuroendocrine and neurotransmitter effects than does 
TNF-α.38,39 However, since the systemic doses of TNF-α 
that were used in the present study were 10-fold higher than 
those of IL-1β, it is not entirely surprising that the former 
cytokine had more potent actions on cell proliferation. 
Moreover, TNF-α has a more prominent role than IL-1β in a 
number of inﬂ  ammatory immune processes, including acute 
phase reactions and T and NK cell cytotoxicity.40 As well, 
TNF-α may have inﬂ  uenced hippocampal cellular survival 
by activating apoptotic cascades.41 Interestingly, in fact, the 
two TNF-a receptors, TNFR-1 (which possess a caspase-
linked intra-cellular death domain) and TNFR-2, appear to 
differentially inﬂ  uence neurogenesis, such that inhibition of 
the former enhanced hippocampal neurogenesis, whereas 
ablation of TNFR-2 reduced neurogenesis.42 Thus, the more 
potent effects of TNF-α on cell proliferation may stem from 
multiple immunological, hormonal or apoptotic processes 
associated with the cytokine. However, since only a single 
dose of each cytokine was used, taken together with the pos-
sibility that differing dose-response relationships might exist 
between different cytokines,43 it may be that other doses of 
IL-1β or IL-6 would exert more marked effects on cellular 
proliferation.
There are several potential routes through which the 
systemically injected cytokines might have inﬂ  uenced hip-
pocampal cellular proliferation. Although cytokines do not 
readily penetrate the blood–brain barrier (BBB) (owing to 
their size and charge), they can cross at “leaky” BB regions, 
including the median eminence region of the hypothala-
mus, as well as other circumventricular sites, including the 
subfornical region.54,55 Speciﬁ  c carrier mediate transport 
mechanisms have also been reported to transport certain 
cytokines across the BBB56 and cytokine administration itself 
(eg, TNF-α) may disrupt BBB integrity.57 As well, several 
cytokines were reported to trigger the transcription of genes 
at cells of the BBB including NF-κB and COX-2, and these 
factors then promoted signaling within the CNS.58 Hence, any 
of these potential routes might explain how the peripheral 
cytokine treatments altered hippocampal BrdU expression.
Central cytokine infusion 
and hippocampal cellular proliferation
In contrast to the effects of systemic TNF-α, repeated intra-
hippocampal infusion of IL-6 and to a lesser degree IL-1β, 
increased the number of BrdU-positive cells in the dentate 
gyrus, suggesting possible pro-mitotic effects of these cyto-
kines. It is unclear why intra-hippocampal cytokine infusion 
had consequences so remarkably different from that observed 
following systemic administration. It may be that sufﬁ  ciently 
high concentrations of the cytokines did not reach the hip-
pocampus following their systemic administration. The 
fact that repeated but not a single intra-hippocampal IL-6 Neuropsychiatric Disease and Treatment 2009:5 13
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infusion markedly elevated BrdU staining suggests that the 
passage of time following introduction of the cytokine may 
be fundamental to the cytokine’s actions or alternatively, that 
a single infusion alone was not a sufﬁ  ciently potent challenge 
to inﬂ  uence hippocampal cellular proliferation. It is pos-
sible that IL-6 may have promoted cellular proliferation by 
enhancing the production of growth factors from microglia or 
astrocytes,44 particularly given that IL-6 elevated expression 
of the microglial marker, CD11b, within the hippocampus.
Consistent with the IL-6-induced changes in cell prolif-
eration, several studies indicated that this cytokine inﬂ  uenced 
the survival, proliferation and differentiation of a variety of 
CNS cells.45–48 These diverse actions appeared to be cell-
speciﬁ  c and dependent upon the particular experimental 
preparation. In fact, while Vallières and colleagues reported a 
suppression of hippocampal neurogenesis in adult transgenic 
mice over-expressing IL-6, the cytokine actually enhanced 
astrogliogenesis, microgliosis and oligodendrogenesis.31 
These reports, together with the enhanced CD11b staining 
we observed in the DG, suggest that the elevated BrdU stain-
ing observed following repeated IL-6 infusion may reﬂ  ect 
augmented gliogenesis rather than neurogenesis. However, 
given that IL-6 receptors are found on DG endothelial cells,52 
coupled with ﬁ  ndings showing that a large proportion of 
diving DG cells express endothelial markers and that IL-6 
enhanced the in vitro proliferation of endothelial cells,53 
also raises the possibility that the cytokine might have also 
affected this cell population. It is also conceivable that the 
unavoidable injury caused by cannula implantation (even 
after the several days of convalescence) may have promoted 
the activation of local inﬂ  ammatory factors, thereby inﬂ  u-
encing the impact of subsequently administered IL-1β or 
IL-6. In this regard, it may be that surgical injury sensitized 
inﬂ  ammatory processes, just as immune (LPS) or traumatic 
insults (stroke) had long term consequences upon neuroin-
ﬂ  ammatory responding.5,49,50
Conclusions and future directions
The present findings suggest that central and systemic 
administration of proinﬂ  ammatory cytokines inﬂ  uenced 
hippocampal cellular proliferation and that these effects 
were dependent upon chronicity and route of administra-
tion. Indeed, systemic but not central TNF-α reduced BrdU, 
supporting the notion that this cytokine impaired cellular 
proliferation by acting upon peripheral targets. Conversely, 
repeated central infusion of IL-6 increased labelling of BrdU 
and the microglial marker, CD11b, suggesting that chroni-
cally elevated hippocampal levels of the cytokine increased 
the proliferation of microglia and possibly other cells. It is 
important to consider that since mice were sacriﬁ  ced 24 hours 
following BrdU administration, cells labelled with this 
mitotic marker were at a very immature stage of development 
and hence, it is possible that after more protracted intervals 
different results may have been obtained. In this regard, it is 
conceivable that the cytokine treatments might inﬂ  uence the 
maturation or long term survival of neurons and glial cells. 
Nevertheless, the present results indicate that cytokines dif-
ferentially inﬂ  uenced the early stages of production and/or 
proliferation of cells of the dentate gyrus.
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